Celdaz 200mg injection is an antineoplastic drug belonging to the class of alkylating agents, containing the active ingredient Dacarbazine. It is used to prevent and treat metastatic malignant melanoma (skin cancer), Hodgkin's disease (cancer that forms in the lymph system, part of the immune system).

It is often combined with cisplatin, a cytotoxic agent, to treat certain types of cancers for the treatment of Hodgkin's lymphoma, and also combined with temozolomide for the treatment of melanoma. There may be an increased risk of certain types of skin cancer (non-melanoma skin cancer) with the use of this medicine. This drug is contraindicated in pregnant women, and women of childbearing potential should use effective contraception during and for at least 6 months after treatment with the drug. It is not known whether it is excreted in human milk, so breastfeeding should be avoided during treatment with the drug. It should also be used with caution in patients with pre-existing liver or kidney dysfunction. You should not have a live vaccine if you are having this injection. This is because it may weaken your immune system and make you more likely to catch a serious infection. Consult your doctor immediately for more advice.

Celdaz 200mg injection may cause pain along the vein. If you feel pain, tell your nurse straight away so that the infusion site can be checked. They may give the drug more slowly or flush it through with more fluids to reduce pain. Treatment should not be started if your white blood cells (leukocytes) have fallen to counts below determined levels. Your doctor will determine these values at regular intervals. This medicine should not be used if you are allergic to this drug. Before each administration, you will have blood tests to check that you have enough blood cells to receive this medicine. It is usually administered once every three to four weeks. Tell your physician about all the medications you have been taking recently, including herbal medicines and supplements, before taking this injection.

Metastatic malignant melanoma

Hodgkin’s disease

It is a type of alkylating agent, which works majorly through the process of alkylation. It enters the cancer cells after getting activated by the liver and inhibits DNA synthesis. This process disrupts the normal cell cycle and DNA function, leading to arrest in cancer cell growth and multiplication.

The medicine will be administered to you by a healthcare professional in a hospital setting. Celdaz 200mg injection will be given intravenously into a vein in your arm or hand. Do not self-administer this medicine. The specific dose and schedule of administration depend on the type and stage of the cancer being treated. This injection is usually given about 30 minutes before you receive your anti-cancer medicine (chemotherapy). During the infusion, you will be monitored for any side effects or reactions to the medication. It is important to get the dose at the scheduled time. If you missed the schedule, contact your doctor and reschedule the dose.

Sore throat or high temperature indicating infection

Unusual bleeding or bruising

Severe vomiting or diarrhea

Extreme tiredness

Severe allergic reaction, characterized by swelling of hands, feet, ankles, face, lips, mouth or throat; rashes or giddiness.

Headache, vision problems, fits, confusion, lethargy or numbness of face

Severe liver problems

Low levels of RBC, WBC and platelets in blood.

Loss of appetite

Nausea, vomiting

Hair loss

Skin reactions

Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Celdaz 200mg injection and reduce effectiveness by causing undesirable side effects.

Store Celdaz 200mg injection in the refrigerator (2°-8°C).

Do not freeze.

Keep it out of reach from children and pets.

Celdaz 200mg injection can cause harm to a developing fetus or nursing baby, so it is important to discuss contraception options and the need to avoid breastfeeding during treatment. This drug causes fatigue, so encourage the patient to take enough rest and self-care during treatment. It increases the risk of bleeding and bruising, so it is important to be careful when using sharp objects or participating in activities that may result in injury.